pharma · HIV-1 Infection · HIV-1 infection
Gilead Sciences
Gilead Sciences Pty Limited
Gilead Sciences Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include HIV-1 Infection, HIV-1 infection, Primary Biliary Cholangitis, Non-small cell lung cancer, Locally Advanced/Metast
Company details
- Status
- Public
- HQ
- 333 Lakeside Drive, Foster City, CA 94404, US
- Founded
- 1987
- Employees
- 14,602
- Programs
- 30
- Drugs
- 54
- Patents
- 0
Quick answer
Gilead Sciences Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include HIV-1 Infection, HIV-1 infection, Primary Biliary Cholangitis, Non-small cell lung cancer, Locally Advanced/Metastatic Urothelial Cancer. NovaPharmaNews links 30 clinical program(s), 8 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (19), phase 2 (7), phase 1 (3).
Company snapshot
Gilead Sciences, Inc. ([/ˈɡɪliəd/](en.wikipedia.org/wiki/Help:IPA/English)) is an American [biopharmaceutical](en.wikipedia.org/wiki/Biopharmaceutical) company headquartered in [Foster City, California](en.wikipedia.org/wiki/Foster_City,_Calif), that focuses on researching and developing [antiviral drugs](en.wikipedia.org/wiki/Antiviral_drug) used in the treatment of [HIV/AIDS](en.wikipedia.org/wi
- 3 approved product(s) across US/EU regulatory metadata.
- 30 active pipeline program(s) linked via ClinicalTrials.gov.
- 30 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Gilead Sciences. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- deal
Gilead's $140M Deal with Yuhan: What It Means for Pharma
- approval
ESMO 2025 Preview: Astra and Daiichi vs. Gilead
- approval
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
- approval
Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis
- approval
Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials
- approval
Lenacapavir posts 100% HIV prevention in PURPOSE 1: what it means
- approval
Lenacapavir posts 100% HIV prevention in PURPOSE 1
- trial_data
Merck and Gilead report mixed outcomes in lung cancer and HIV studies
Recent coverage
Merck and Gilead report mixed outcomes in lung cancer and HIV studies
Merck Gilead report mixed outcomes in key lung cancer and HIV studies: a Phase 3 Trodelvy plus KEYTRUDA lung cancer trial was halted, while two Phase 3 HIV studies for islatravir/lenacapavir reported positive topline results. This plan focuses on the business and clinical implications for analysts and BD teams.
KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
This page should frame the KRX English IR reference as a company disclosure/investor-relations document and give readers a concise way to navigate its purpose and likely themes. Keep the summary factual and avoid adding performance or product claims not present in the source.
Lenacapavir posts 100% HIV prevention in PURPOSE 1
Gilead’s lenacapavir posted 100% efficacy in the Phase 3 PURPOSE 1 trial for HIV prevention in cisgender women. The result strengthens the case for Lenacapavir PrEP and raises the stakes for Gilead’s next regulatory and clinical catalysts.
Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials
Gilead’s lenacapavir PrEP has emerged as a high-efficacy HIV prevention asset after Phase 3 results showed strong protection versus comparators. This plan focuses on what changed, why it matters for investors and BD teams, and the next catalysts to watch.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Marketed / approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Gilead Sciences.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Gilead Sciences.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Gilead Sciences?
-
Is Gilead Sciences publicly traded?
-
What drugs does Gilead Sciences develop or market?
-
What are the latest developments for Gilead Sciences?
-
What therapeutic areas does Gilead Sciences focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.